Iterion Announces First Patient Dosed in Phase 1b/2a Trial of Tegavivint
HOUSTON, May 16, 2023 /PRNewswire/ -- Iterion Therapeutics, a leading biopharmaceutical company dedicated to the development of innovative treatments for cancer, announced today its collaboration in a Phase 1 clinical trial for tegavivint in patients with relapsed or refractory c-Myc-overexpressing large B-cell lymphomas. The first patient has been enrolled to this National Cancer Institute-funded study, which is being conducted at The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute in Columbus, Ohio.
Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics, today announced that results ...
HOUSTON, April 8, 2022 /PRNewswire/ -- Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics, today announced that three posters involving research into tegavivint will be presented at the 2022 American Association for Cancer Research (AACR) Annual Meeting, including initial results from a Phase 1 study of tegavivint in patients with desmoid sarcomas. AACR 2022 is being held April 8-13, 2022, in New Orleans.
Iterion Therapeutics has announced the start of a Phase I/II clinical trial to assess tegavivint in treating paediatric cancers
Iterion Therapeutics has announced the start of a Phase I/II clinical trial to assess tegavivint in treating paediatric cancers.
Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company, announced the initiation of a phase 1 clinical trial to investigate tegavivint as a potential treatment for acute myeloid leukemia (AML). This investigator-initiated trial is being led by Tapan M. Kadia, M.D., from the Department of Leukemia at The University of Texas MD Anderson Cancer Center.
HOUSTON, July 28, 2020 /PRNewswire/ -- Iterion Therapeutics, Inc., a venture-backed, clinical stage biotechnology company developing novel cancer therapeutics, announced today that enrollment has commenced in its multicenter Phase 2a dose expansion clinical study of Tegavivint, a novel, potent and selective nuclear ?-catenin inhibitor, in patients with desmoid tumors. The Phase 2a trial builds on a recently completed open-label, non-randomized Phase 1 study that established safety and initial clinical efficacy of Tegavivint in patients with progressive desmoid tumors.